Cargando…

Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry

PURPOSE: To assess the impact of concomitant emphysema on outcomes in patients with idiopathic pulmonary fibrosis (IPF). METHODS: The IPF-PRO Registry is a US registry of patients with IPF. The presence of combined pulmonary fibrosis and emphysema (CPFE) at enrollment was determined by investigators...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyun J., Snyder, Laurie D., Neely, Megan L., Hellkamp, Anne S., Hotchkin, David L., Morrison, Lake D., Bender, Shaun, Leonard, Thomas B., Culver, Daniel A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Combined Pulmonary Fibrosis and Emphysema
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881259/ https://www.ncbi.nlm.nih.gov/pubmed/34997268 http://dx.doi.org/10.1007/s00408-021-00506-x

Ejemplares similares

Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort
por: Todd, Jamie L., et al.
Publicado: (2022)

Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry
por: Snyder, Laurie D, et al.
Publicado: (2020)

Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
por: de Andrade, Joao A., et al.
Publicado: (2022)

Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry
por: Snyder, Laurie, et al.
Publicado: (2019)

Lung emphysema revisited
por: Redwan, Bassam
Publicado: (2020)

Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry
por: Swaminathan, Aparna C., et al.
Publicado: (2022)

Lung transplantation for emphysema
por: Inci, Ilhan
Publicado: (2020)

Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
por: Salisbury, Margaret L., et al.
Publicado: (2020)

Anesthesiological considerations in emphysema surgery
por: Woldt, Philip, et al.
Publicado: (2020)

Advances in imaging for lung emphysema
por: Martini, Katharina, et al.
Publicado: (2020)

Blood Cell Count Derived Inflammation Indexes in Patients with Idiopathic Pulmonary Fibrosis
por: Zinellu, Angelo, et al.
Publicado: (2020)

Progranulin and Activin A Concentrations are Elevated in Serum from Patients with Acute Exacerbations of Idiopathic Pulmonary Fibrosis
por: Xie, Tian, et al.
Publicado: (2021)

Lung emphysema and lung cancer: what do we know about it?
por: Tubío-Pérez, Ramón A., et al.
Publicado: (2020)

Lung volume reduction surgery: from National Emphysema Treatment Trial to non-intubated awake video-assisted thoracoscopic surgery
por: Kösek, Volkan, et al.
Publicado: (2020)

Lung function in children with cystic fibrosis in the USA and UK: a comparative longitudinal analysis of national registry data
por: Schlüter, Daniela K, et al.
Publicado: (2022)

Acceptability of patient reported outcome measures (PROMs) in a cystic fibrosis data registry
por: Ratnayake, Irushi, et al.
Publicado: (2021)

Registry-based study in people with cystic fibrosis and an R117H variant treated with ivacaftor
por: Higgins, Mark, et al.
Publicado: (2023)

Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
por: Bessonova, Leona, et al.
Publicado: (2018)

Associations between Patient-reported Outcomes and Death or Lung Transplant in Idiopathic Pulmonary Fibrosis. Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry
por: Case, Amy Hajari, et al.
Publicado: (2020)

Impact of newborn screening on outcomes and social inequalities in cystic fibrosis: a UK CF registry-based study
por: Schlüter, Daniela K, et al.
Publicado: (2020)

Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials
por: Keogh, Ruth H, et al.
Publicado: (2022)

Emulated trial investigating effects of multiple treatments: estimating combined effects of mucoactive nebulisers in cystic fibrosis using registry data
por: Granger, Emily, et al.
Publicado: (2023)

Eradication of Pseudomonas aeruginosa in adults with cystic fibrosis
por: Kenny, S L, et al.
Publicado: (2014)

Effective silencing of ENaC by siRNA delivered with epithelial-targeted nanocomplexes in human cystic fibrosis cells and in mouse lung
por: Tagalakis, Aristides D, et al.
Publicado: (2018)

Validation and use of a parametric model for projecting cystic fibrosis survivorship beyond observed data: a birth cohort analysis
por: Jackson, Abaigeal D, et al.
Publicado: (2011)

Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure
por: Ceelen, Daan, et al.
Publicado: (2022)

Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection
por: Clancy, J P, et al.
Publicado: (2013)

Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial
por: Nichols, David P, et al.
Publicado: (2022)

Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis
por: Dorkin, Henry L, et al.
Publicado: (2015)

Downregulation of epithelial sodium channel (ENaC) activity in human airway epithelia after low temperature incubation
por: Yadav, Sangya, et al.
Publicado: (2021)

Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosis
por: Knibbs, Luke D, et al.
Publicado: (2014)

Survival models to support shared decision-making about advance care planning for people with advanced stage cystic fibrosis
por: Hajizadeh, Negin, et al.
Publicado: (2021)

International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety
por: Quittner, Alexandra L, et al.
Publicado: (2016)

Delayed neutrophil apoptosis enhances NET formation in cystic fibrosis
por: Gray, Robert D, et al.
Publicado: (2018)

Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design
por: Jain, Raksha, et al.
Publicado: (2022)

Impact of cystic fibrosis on birthweight: a population based study of children in Denmark and Wales
por: Schlüter, Daniela K, et al.
Publicado: (2019)

Cough-generated aerosols of Pseudomonas aeruginosa and other Gram-negative bacteria from patients with cystic fibrosis
por: Wainwright, C E, et al.
Publicado: (2009)

Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age
por: Byrnes, Catherine Ann, et al.
Publicado: (2013)

Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry
por: Todd, Jamie L., et al.
Publicado: (2019)

Increased extracellular vesicles mediate inflammatory signalling in cystic fibrosis
por: Useckaite, Zivile, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_etp04sdjnnapj14ilq5r28gd8a